secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neumora Therapeutics, Inc. (NMRA)
CIK:        0001885522
Form:       8-K
Filed at:   2025-10-27T23:59:59+00:00
Accession:  0001193125-25-250677
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neumora starts Phase 1 study of second M4 PAM, NMRA-898; no convulsions in preclinical
--------------------------------------------------------------------------------

- Initiated Phase 1 SAD/MAD study of NMRA-898, an M4 positive allosteric modulator for schizophrenia and neuropsychiatric disorders.
- NMRA-898 is structurally distinct from NMRA-861 (Phase 1 started July 2025); both may offer best-in-class pharmacology.
- No convulsions observed in preclinical studies across multiple species, including rabbits.
- Neumora expects to provide a comprehensive M4 franchise update by mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/0001193125-25-250677-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1885522/000119312525250677/nmra-20251027.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-250677

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer